Bruce Cohen, Venture Partner, Xeraya Capital (Moderator)
Bruce Cohen is a Venture Partner with Xeraya Capital and CEO of Anergent Pharmaceuticals. He was the founding President and CEO of Acacia Biosciences, Cellerant Therapeutics and VitaPath Genetics. He also served as CFO at GeneSoft Pharmaceuticals and held senior positions in business development and marketing at Sequus Pharmaceuticals and at Baxter. Bruce holds a BA, cum laude and an MA from Tufts University, as well as an MBA with distinction from Harvard Business School.

Nat Brinn, Partner, VC23
Nat Brinn has a successful track record of venture capital and other private investments, acquisitions, corporate development and business management. He is a partner of VC23 and Vital Venture Capital. Nat’s venture capital firms and he, as a direct investor, have invested in over 40 early-stage biotechnology and software companies including Gingko Bioworks, Quantalife (acquired by Bio-Rad), Twist Bioscience (now publicly traded with a market cap in excess of $750 million), 10X Genomics (now publicly traded with a market cap in excess of $6 billion), AxioMx (acquired by Abcam), HealthTell (acquired by iCarbonX), CD Diagnostics (acquired by Zimmer), General Automation Lab Technologies, Tangen Biosciences, Talee Bio (acquired by Roivant), and Shoreline Biome. Nat has served as a board director of many of these portfolio companies.

Deborah Hemingway, Managing Partner, Ecphora Capital
Dr. Deborah Hemingway is the Founder & Managing Partner of Ecphora Capital, an early-stage medtech venture capital firm in Baltimore, Maryland. Dr. Hemingway has had extensive activity in the entrepreneurial ecosystem having founded, funded, or held board positions at 53 companies. Throughout her 20+ years of entrepreneurial experience, she honed her expertise in medical device commercialization, strategic growth, and investing. Dr. Hemingway holds a Ph.D. in biophysics from the University of Maryland, College Park.

Hannah Mamuszka, Managing Partner, 10Edison Capital
Hannah Mamuszka is Managing Director at 10Edison Capital, a new venture capital fund focused on early stage and early market diagnostic companies. She is also the Founder of Alva10, which she started in 2016 to bridge the gap between payors and diagnostic developers to align on value and evidence thresholds. Hannah is a frequent speaker and writer on driving change in healthcare, and is on the editorial board for the Journal of Precision Medicine, where she also writes a regular column on the challenges of implementing change in medicine. Hannah serves on the Board of Directors for Bionano Genomics (BNGO) and the University of North Carolina’s Carolina Health Informatics Program (CHIP).

James Murray, Partner, ExSight Ventures
James is a co-founder and partner at ExSight Ventures where he has helped lead the firm’s investments in twelve transformative ophthalmic companies, including two diagnostic companies: Envision Diagnostics and Novai. He serves on the boards of Re-Vana Therapeutics, a Northern Ireland pharmaceuticals and drug delivery company, the Usher III Initiative, a nonprofit dedicated to finding treatments for Usher III patients, and Nectar Services, an unaffiliated UCaaS company. James is a board observer at 2C Tech, a pioneering nanoparticle company. He is admitted to practice in the State of New York and is a member of the Association of the Bar of the City of New York where he served as Chair of the Emerging Companies and Venture Capital Committee.

Soyoung Park, General Partner, 1004 Venture Partners
Soyoung is a visionary leader who aims to keep people healthy through transformative longevity technologies and healthcare infrastructures. During 15+ years of extensive experience in entrepreneurship and investment, Soyoung has invested in 20+ emerging life sciences companies and contributed to the exits of 3 companies through acquisitions, including Nellix Endovascular (acquired by Endologix), Hotspur Technologies (acquired by Teleflex) and GBT (sold to Pfizer). She also serves as a mentor and speaker for numerous reputable global accelerators and life science conferences, sharing her wealth of knowledge and experience with the next generation of leaders. Soyoung holds an MBA from the Fuqua School of Business at Duke University, with a focus on Health Sector Management and Strategy.